Blood News and Research

RSS

New vascularized grafts may improve bladder surgery for children

Can growing blood vessels within a lab-engineered graft improve bladder reconstruction for children? For more than two decades, UC Davis pediatric urologic surgeon Eric Kurzrock has been developing and testing grafts to avoid the complications after standard enterocystoplasty, a surgery for bladder augmentation.

12 Jun 2026

WHO data shows progress and persistent gaps in safe blood supply

New data from the World Health Organization (WHO) show sustained progress towards safer blood supplies globally but also highlight persistent inequalities in access to safe blood and weaknesses in governance, financing and regulation of blood systems.

12 Jun 2026

Review outlines virtual tumor concept and next-generation immunotherapy

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

12 Jun 2026

Antibody profiles offer insights into long Covid cognitive symptoms

Persistent symptoms after COVID-19 infection continue to affect millions of people worldwide, even as the number of acute infections has declined.

12 Jun 2026

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers.

From PhoreMost 12 Jun 2026

New combination therapy improves outcomes in high-risk leukemia

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment outcomes and survival in patients with acute myeloid leukaemia (AML) with FLT3 gene mutations.

11 Jun 2026

Scientists uncover protein-folding mechanism linked to diabetes progression

Origami masters turn simple sheets of paper into ornate sculptures. In the origami of life, our cells must fold proteins into specific three-dimensional shapes before they can carry out their biological jobs.

11 Jun 2026

Childhood lead exposure declines but disparities persist nationwide

Blood lead levels in young children in the United States declined in the last decade, but state data reveal that children of color and children from low-wealth families are still exposed to higher levels of lead, according to a new study in the American Journal of Public Health.

11 Jun 2026

Laser phase plate dramatically expands cryo-EM imaging capabilities

In a landmark achievement in biological imaging, researchers at the University of California, Berkeley and Biohub today announced the successful demonstration of the laser phase plate, a novel device that dramatically improves the contrast of images produced by cryo-electron microscopes, opening up an entirely new view of human biology.

11 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Trial finds prunes do not outperform calcium and vitamin D for male bone density

A one-year randomized trial found that daily prune supplementation did not improve total or lumbar spine bone mineral density in older men susceptible to, or with, osteopenia. Although some bone turnover biomarkers differed between prune and control groups, these changes did not translate into measurable bone density benefits beyond calcium and vitamin D3 supplementation.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

BU professor to examine the role of postpartum hypertension on recurrent HDP risk

Samantha Parker Kelleher, along with researchers at BU School of Public Health and Boston Medical Center, will examine the role of high blood pressure during the postpartum period on the risk of developing recurrent hypertensive disorders of pregnancy, such as preeclampsia and gestational hypertension.

11 Jun 2026